| Market Capitalization (Millions $) |
953 |
| Shares
Outstanding (Millions) |
107 |
| Employees |
19 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-289 |
| Cash Flow (TTM) (Millions $) |
-161 |
| Capital Exp. (TTM) (Millions $) |
0 |
89bio Inc
89bio Inc. is a clinical-stage biopharmaceutical company that develops therapies for the treatment of liver and cardio-metabolic diseases. It is headquartered in San Francisco, California, and was founded in 2018.
The companyes focus is on developing innovative therapies for nonalcoholic steatohepatitis (NASH) and other liver and cardio-metabolic diseases. NASH is a severe form of nonalcoholic fatty liver disease (NAFLD) that affects about 16 million people in the United States alone. It is characterized by the buildup of fat in the liver, inflammation, and damage to liver cells, which can lead to liver cirrhosis, liver failure, and liver cancer.
89bioes lead product candidate, called BIO89-100, is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist designed to treat NASH. GLP-1 is a naturally occurring hormone that stimulates insulin secretion and reduces appetite. BIO89-100 is designed to improve insulin sensitivity, reduce liver fat, prevent liver inflammation, and improve liver fibrosis.
BIO89-100 has completed a Phase 1b/2a clinical trial in patients with NASH and demonstrated promising efficacy and safety results. The company plans to initiate a Phase 2b clinical trial in the second half of 202
Besides BIO89-100, 89bio has two other product candidates in its pipeline. These are BIO89-050 and BIO89-070, both of which are GLP-1 receptor agonists designed for the treatment of obesity and type 2 diabetes. These product candidates are in preclinical development.
89bio has a team of experienced executives and scientists with a track record of developing successful therapies for liver diseases. The company is backed by a group of leading biotechnology investors, including RA Capital, OrbiMed Advisors, Vivo Capital, Cormorant Asset Management, and Aju IB Investment.
In summary, 89bio is a clinical-stage biopharmaceutical company that develops innovative therapies for the treatment of liver and cardio-metabolic diseases, with a particular focus on NASH. Its lead product candidate, BIO89-100, has demonstrated promising efficacy and safety in a Phase 1b/2a clinical trial and is expected to enter a Phase 2b clinical trial in the second half of 202 The company also has two other product candidates in preclinical development for the treatment of obesity and type 2 diabetes.
Company Address: 655 Montgomery Street San Francisco 94111 CA
Company Phone Number: 432-9270 Stock Exchange / Ticker: NASDAQ ETNB
|
1.77% 